Company Overview of IRRAS AB
IRRAS AB manufactures and markets products in the fields of neurosurgery, infectious diseases, and oncology. It offers a technology platform that is used as a treatment modality for hemorrhagic stroke, malignant tumors, and infectious diseases. IRRAS AB was founded in 2011 and is based in Stockholm, Sweden.
Founded in 2011
Key Executives for IRRAS AB
Senior VP of Commercial Operations & GM of Europe
Chief Medical Officer and Director
Vice President of Product Development
Compensation as of Fiscal Year 2017.
IRRAS AB Key Developments
IRRAS Announces Two Key Appointments to Its Executive and Commercial Teams
Sep 13 17
IRRAS announced two key appointments to its executive and commercial teams: Karl-Matthias Moehlmann as Senior Vice President Commercial Operations, General Manager Europe and a member of the executive management team, and Klemens Flling as Director of International Sales. Collectively, Mr. Moehlmann and Mr. Flling bring over 40 years of experience in developing, launching, marketing and selling medical devices for neurological applications. Prior to their appointments as full-time employees, Mr. Moehlmann and Mr. Flling served as senior advisors to IRRAS.
Irras AB Appoints Fredrik Alpsten as Chief Financial Officer and Deputy Chief Executive Officer and A Member of the Executive Management Team
Aug 30 17
IRRAS announced the appointment of Fredrik Alpsten as Chief Financial Officer and Deputy Chief Executive Officer and a member of the executive management team. Mr. Alpsten brings approximately 20 years of operational, financial, and strategic business experience as an executive in the medical technology field. In his new role, Mr. Alpsten will report directly to the CEO of IRRAS, Kleanthis G. Xanthopoulos, Ph.D., from the Stockholm, Sweden site. IRRAS expects Mr. Alpsten to join during early 2018 at the latest. Most recently, Mr. Alpsten, as a member of the executive management team, served as Senior Vice President and CFO of Boule Diagnostics AB (Boule). During his six years in this role, Mr. Alpsten was responsible for overseeing multiple global departments including finance, investor relations, administration, IT, legal, human resources, and facilities. During his time at Boule, Mr. Alpsten also served as President and CEO of Clinical Diagnostic Solutions Inc. Prior to that, for three years he was President and CEO of Doxa AB (Doxa). Before serving as President and CEO at Doxa, Mr. Alpsten was VP, CFO of Doxa for eight years and prepared the company for an Initial Public Offering on the Nasdaq exchange. Mr. Alpsten also served as Finance Director of N&T Argonaut AB for nine years. In addition to different board assignments for the Boule group, Mr. Alpsten currently serves as Chairman of the Board of Personlig Almanacka Nordic AB and board member and chairman of the audit committee of Oniva Online Group Europe AB.
IRRAS Appoints C. Lance Boling as Vice President, Product Development
Apr 10 17
IRRAS announced the appointment of C. Lance Boling as Vice President, Product Development and a member of the executive management team. Mr. Boling brings over 25 years of experience in medical device development, manufacturing, and operations to IRRAS, where he will be responsible for expanding the IRRAflow
technology portfolio in both the EU and U.S. In his role, Mr. Boling will report directly to the Chairman and CEO of IRRAS, Kleanthis G. Xanthopoulos, Ph.D., from one of the company's U.S. sites. Prior to joining IRRAS, Mr. Boling was Director of Nano Technology Development at Abbott Laboratories where he was responsible for leading numerous development efforts from inception through commercialization. Before Abbott, Mr. Boling held leadership positions at Nanostim, Nevro Corporation, NeuroPace Inc., and Autonomic Technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|